Elite Pharmaceuticals elects Aqeel A. Fatmi and John W. LaRocca to board
Thời gian đọc: dưới 1 phút
Elite Pharmaceuticals elected Aqeel A. Fatmi and John W. LaRocca to its board, effective October 28, 2026.
| Individual | Aqeel A. Fatmi, Ph.D. | John W. LaRocca, Esq. |
| Role | Class II director | Class I director |
| Type of Change | Elected to the board | Elected to the board |
| Effective Date | October 28, 2026 | October 28, 2026 |
| Term | Until the next annual meeting of stockholders and until a successor is elected and qualified, or earlier death, resignation or removal | Until the next annual meeting of stockholders and until a successor is elected and qualified, or earlier death, resignation or removal |
| Reason | Not disclosed | Not disclosed |
| Board/Committee Role Changes | No committee assignment yet | No committee assignment yet |
| Compensation/Agreement Terms | Will receive compensation in the same manner as the board’s other non-management directors | Will receive compensation in the same manner as the board’s other non-management directors |
| Background Details | More than four decades in pharmaceuticals and biopharmaceuticals; has served as an independent strategic and technical advisor since 2016. | More than three decades of legal experience, including over two decades in pharmaceuticals; has held senior legal roles at several pharmaceutical companies. |
Original SEC Filing: ELITE PHARMACEUTICALS INC /NV/ [ ELTP ] - 8-K - Nov. 03, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.